(HealthDay News) — Factors showing increased risk for cardiometabolic disorders are present in patients with first-episode schizophrenia spectrum disorders (FES), according to research published in JAMA Psychiatry.

Christoph U. Correll, MD, of the Zucker Hillside Hospital in Glen Oaks, New York, and colleagues examined cardiometabolic data for 394 patients aged 15 to 40 years (mean age, 23.6 years) who had FES and a lifetime antipsychotic treatment duration averaging 47.3 days.

The researchers found that 56.5% had dyslipidemia, 50.8% smoked, 48.3% were obese, 39.9% had prehypertension, 13.2% had metabolic syndrome and 10.0% had hypertension. Prediabetes (glucose based, 4.0%; HbA1c based, 15.4%) and diabetes (glucose based, 3.0%; HbA1c based, 2.9%) were found less frequently.

Continue Reading

Total duration of psychiatric illness was associated with higher BMI, fat mass, fat percentage and waist circumference (all P<.01) and elevated triglycerides to HDL cholesterol ratio (P=.04). Duration of antipsychotic treatment was associated with higher levels of non-HDL, triglycerides, and triglyceride to HDL-C ratio, and lower levels of HDL and systolic blood pressure (all P≤.01).

“In patients with FES, cardiometabolic risk factors and abnormalities are present early in the illness and likely related to the underlying illness, unhealthy lifestyle, and antipsychotic medications, which interact with each other,” the researchers wrote.

Several authors disclosed financial ties to pharmaceutical and biomedical companies.


  1. Correll CU et al. JAMA Psychiatry. 2014;doi:10.1001/jamapsychiatry.2014.1314.